Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 59
Appendix A
Workshop Agenda
New Paradigms in Drug Discovery: How Genomic Data Are Being
Used to Revolutionize the Drug Discovery and Development Process--
A Workshop
March 21, 2012
20 F Street NW Conference Center
20 F Street, NW
Washington, DC 20001
WORKSHOP OBJECTIVES
· To examine the impact of and investment in the use of genetic and
genomic data in drug development.
· To discuss how genomic and genetic data have been and will be
used in the drug development process to improve aspects such
as target identification, clinical trial design, pharmacogenomic
approaches, biomarker development, and understanding of disease
biology.
· To investigate the economic drivers, incentives, and models for
genomic-based strategies for drug development.
59
OCR for page 60
60 GENOME-BASED THERAPEUTICS
8:308:35 A.M. WELCOMING REMARKS
Wylie Burke, Roundtable Chair
Professor and Chair, Department of Bioethics and
Humanities, University of Washington
8:358:45 A.M. HARGE TO WORKSHOP SPEAKERS AND
C
PARTICIPANTS
Geoffrey Ginsburg
Director, Center for Genomic Medicine,
Duke University
8:4510:15 A.M. CURRENT LANDSCAPE
Session Moderator: Aidan Power, Pfizer Inc.
8:459:00 A.M.Current Use of Genetic and Genomic Strategies in
Drug Development
Nicholas Davies
Partner, Pharmaceutical and Life Sciences Practice,
PwC
9:009:15 A.M.Economic Incentives for Genetic and Genomic
Strategies
Mark Trusheim
Visiting Scientist and Executive-in-Residence,
MIT Sloan School of Management; President,
Co-Bio Consulting
9:159:30 A.M.Perceived Challenges in Genomic-Based Drug
Development
Garret A. FitzGerald
Professor of Medicine and Pharmacology and
McNeil Professor in Translational Medicine and
Therapeutics; Associate Dean for Translational
Research; Chair, Department of Pharmacology;
Director, Institute for Translational Medicine and
Therapeutics, University of Pennsylvania School of
Medicine
OCR for page 61
APPENDIX A 61
9:3010:15 A.M. Discussion with Speakers and Attendees
10:1510:30 A.M. BREAK
10:30 A.M. DRUG DISCOVERY AND DEVELOPMENT:
12:15 P.M. CASE STUDIES OF GENOMICS-BASED DRUG
DEVELOPMENT
Session Moderator: Michelle Penny,
Eli Lilly and Company
10:3010:50 A.M.Development of Crizotinib for Treatment of Non-
Small-Cell Lung Cancer
Steffan N. Ho
Director, Translational Oncology, Pfizer Inc.
10:5011:10 A.M.Use of Genetics to Inform Drug Development of a
Novel Treatment for Schizophrenia
Laura Nisenbaum
Senior Research Advisor, Pharmacogenomics,
Translational Medicine and Tailored Therapeutics,
Eli Lilly and Company
11:1011:30 A.M.A Genetic Approach to the Treatment of Cystic
Fibrosis
Peter Mueller
Executive Vice President, Global Research and
Development; Chief Scientific Officer, Vertex
Pharmaceuticals Incorporated
11:30 A.M. Discussion with Speakers and Attendees
12:15 P.M.
12:151:00 P.M. WORKING LUNCH
OCR for page 62
62 GENOME-BASED THERAPEUTICS
1:002:15 P.M.UTILITY OF EMERGING GENOMICS
TECHNOLOGY IN DRUG DEVELOPMENT
Session Moderator: Geoffrey Ginsburg,
Duke University
1:001:15 P.M.Large-Scale Whole-Genome Sequencing for Disease
Understanding, Drug Development, and Genomic
Medicine
Radoje Drmanac
Co-Founder and Chief Scientific Officer,
Complete Genomics
1:151:30 P.M.Clinical Next Generation Sequencing--Value to Drug
Developers
Gary Palmer
Senior Vice President, Medical Affairs and
Commercial Development, Foundation Medicine
1:301:45 P.M. Pharma Perspective
Jane Fridlyand
Senior Statistical Scientist, Genentech
1:452:15 P.M. Discussion with Speakers and Attendees
2:154:15 P.M. EVOLVING PARADIGMS
Session Moderator: Sharon Terry, Genetic Alliance
2:152:30 P.M. Foundations and Drug Development
Walter Capone
Chief Operating Officer, Multiple Myeloma
Research Foundation
OCR for page 63
APPENDIX A 63
2:302:45 P.M. Genomics and Regulatory Science
Michael Pacanowski
Team Leader, Office of Clinical Pharmacology,
Office of Translational Sciences, Center for Drug
Evaluation and Research, U.S. Food and Drug
Administration
2:453:00 P.M. BREAK
3:003:15 P.M. Repurposing of Drugs
Christopher Austin
Director of the Division of Pre-Clinical
Innovation; Scientific Director, NIH Center for
Translational Therapeutics; National Center
for Advancing Translational Sciences, National
Institutes of Health
3:153:30 P.M.Pharmacy Benefit Management and
Pharmacogenomics
Felix W. Frueh
President, Medco Research Institute
3:304:15 P.M. Discussion with Speakers and Attendees
4:155:30 P.M.LEADING THE STRATEGY FOR
PERSONALIZED MEDICINE:
PHARMA, GOVERNMENT, ACADEMIA--
HOW DO WE ALL WORK TOGETHER?
Session Moderator: Thomas Lehner,
National Institute of Mental Health, National
Institutes of Health
Discussants:
Deborah Dunsire
President and Chief Executive Officer,
Millennium: The Takeda Oncology Company
OCR for page 64
64 GENOME-BASED THERAPEUTICS
Victor Dzau
Chancellor for Health Affairs, Duke University;
President and Chief Executive Officer,
Duke University Health System
Margaret Hamburg
Commissioner,
U.S. Food and Drug Administration
Kathy Hudson
Deputy Director for Science, Outreach, and
Policy; Acting Deputy Director, National Center
for Advancing Translational Sciences,
National Institutes of Health
5:305:45 P.M. CONCLUDING REMARKS
Geoffrey Ginsburg
Director, Center for Genomic Medicine,
Duke University
5:45 P.M. ADJOURN
